Relmada Therapeutics Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Sergio Traversa
Chief executive officer
US$4.8m
Total compensation
| CEO salary percentage | 14.7% |
| CEO tenure | 12yrs |
| CEO ownership | 0.8% |
| Management average tenure | 4.3yrs |
| Board average tenure | 4.3yrs |
Recent management updates
Recent updates
Relmada Therapeutics: Run Up Into Results May Resume Following This Drop
Mar 21Here's Why We're Watching Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Situation
Mar 13
Relmada: Phase 3 Data Did Not Live Up To Phase 2 Benchmark
Jan 14Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Deliver On Growth Plans?
Dec 04Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Invest In Growth?
Aug 29We're Keeping An Eye On Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Rate
May 07We're Keeping An Eye On Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Rate
Dec 15Relmada Downgraded at Truist, Guggenheim in wake of depression candidate failure
Oct 14Relmada Therapeutics: Initiating With A Strong BUY; Key Phase 3 Short-Term Catalysts Lined Up
Sep 14Relmada Therapeutics receives FDA fast track tag for REL-1017 to treat depression
Aug 09We're Hopeful That Relmada Therapeutics (NASDAQ:RLMD) Will Use Its Cash Wisely
Jul 14Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Deliver On Growth Plans?
Feb 264 Clinical Catalysts On Tap For Relmada In 2022
Jan 28Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Invest In Growth?
Nov 04Our First Look At Relmada Therapeutics
Jun 28We're Not Very Worried About Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Rate
Jun 28Here's Why We're Not Too Worried About Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Situation
Mar 09What Percentage Of Relmada Therapeutics, Inc. (NASDAQ:RLMD) Shares Do Insiders Own?
Jan 15
Enrollment underway in Relmada Therapeutics' late-stage depression study with REL-1017
Dec 07Relmada Therapeutics (RLMD) Investor Presentation - Slideshow
Dec 02Relmada Therapeutics (RLMD) Investor Presentation - Slideshow
Nov 16CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | US$5m | US$701k | -US$99m |
| Sep 30 2023 | n/a | n/a | -US$112m |
| Jun 30 2023 | n/a | n/a | -US$129m |
| Mar 31 2023 | n/a | n/a | -US$144m |
| Dec 31 2022 | US$3m | US$668k | -US$157m |
| Sep 30 2022 | n/a | n/a | -US$153m |
| Jun 30 2022 | n/a | n/a | -US$157m |
| Mar 31 2022 | n/a | n/a | -US$143m |
| Dec 31 2021 | US$36m | US$630k | -US$126m |
| Sep 30 2021 | n/a | n/a | -US$112m |
| Jun 30 2021 | n/a | n/a | -US$86m |
| Mar 31 2021 | n/a | n/a | -US$71m |
| Dec 31 2020 | US$900k | US$600k | -US$59m |
| Sep 30 2020 | n/a | n/a | -US$43m |
| Jun 30 2020 | n/a | n/a | -US$30m |
| Mar 31 2020 | n/a | n/a | -US$23m |
| Dec 31 2019 | US$16m | US$214k | -US$15m |
| Sep 30 2019 | n/a | n/a | -US$18m |
| Jun 30 2019 | n/a | n/a | -US$17m |
| Mar 31 2019 | n/a | n/a | -US$17m |
| Dec 31 2018 | n/a | n/a | -US$17m |
| Sep 30 2018 | n/a | n/a | -US$11m |
| Jun 30 2018 | US$975k | US$376k | -US$9m |
| Mar 31 2018 | n/a | n/a | -US$7m |
| Dec 31 2017 | n/a | n/a | -US$6m |
| Sep 30 2017 | n/a | n/a | -US$6m |
| Jun 30 2017 | US$405k | US$350k | -US$6m |
Compensation vs Market: Sergio's total compensation ($USD4.78M) is above average for companies of similar size in the US market ($USD668.06K).
Compensation vs Earnings: Sergio's compensation has increased whilst the company is unprofitable.
CEO
Sergio Traversa (63 yo)
12yrs
Tenure
US$4,778,944
Compensation
Dr. Sergio Traversa, PharmD, MBA has been the Chief Executive Officer and a Director of Relmada Therapeutics, Inc. since April 18, 2012. Dr. Traversa served as Interim Chief Financial Officer at Relmada Th...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 12yrs | US$4.78m | 0.81% $ 902.9k | |
| Chief Financial Officer | 4.3yrs | US$2.34m | 0.12% $ 129.1k | |
| Chief Accounting & Compliance Officer | 4.3yrs | US$2.33m | 0.13% $ 144.2k | |
| Chief Scientific Officer | 3.5yrs | no data | no data | |
| VP & Head of Clinical Operations | 5yrs | no data | no data | |
| Chief Clinical Officer | 3.5yrs | no data | no data | |
| Head of Commercial | 1.8yrs | no data | no data | |
| Senior Clinical Development Advisor | no data | no data | no data | |
| Consultant | 7yrs | no data | no data |
4.3yrs
Average Tenure
62yo
Average Age
Experienced Management: RLMD's management team is considered experienced (4.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 12yrs | US$4.78m | 0.81% $ 902.9k | |
| Chief Financial Officer | 4.3yrs | US$2.34m | 0.12% $ 129.1k | |
| Independent Chairman of the Board | 8.8yrs | US$674.90k | 0% $ 0 | |
| Member of Scientific Advisory Board | 4.3yrs | no data | no data | |
| Member of Scientific Advisory Board | 6.8yrs | no data | no data | |
| Independent Director | 1.3yrs | US$1.33m | 0% $ 0 | |
| Director | 8.4yrs | US$1.67m | 0.62% $ 693.0k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 4.3yrs | US$604.77k | no data | |
| Member of Scientific Advisory Board | 4.3yrs | no data | no data | |
| Member of Scientific Advisory Board | 4.3yrs | no data | no data | |
| Member of Scientific Advisory Board | 4.3yrs | no data | no data |
4.3yrs
Average Tenure
61.5yo
Average Age
Experienced Board: RLMD's board of directors are considered experienced (4.3 years average tenure).